Director, President and Chief Executive Officer. Mr. Thompson is an early investor who was asked to serve as the company’s first outside director when Phoenix was formed in 2003 and has served in that role to the present. He is an attorney and currently lives in Des Moines, Iowa. Prior to agreeing to serve as Phoenix CEO beginning in January 2023, he was employed with the Iowa Department of Justice, where he served as Solicitor General. Mr. Thompson previously was in private practice and specialized in civil litigation. He also previously held management positions in the oilfield services industry and has served on non-profit boards.
J.P. Bryan, Jr.
J.P. Bryan, Jr., Chairman and Director. Mr. Bryan began his business career in banking and investment banking with JP Morgan, Dominick & Dominick and EF Hutton, frequently working in medical industry transactions. He has spent more than four decades in the oil and gas industry – including serving as CEO and President of Gulf Canada Resources, founder and chairman of Torch Advisors and executive and board involvement in other energy companies. He has served on the corporate boards of AutoNation, Torchmark Corp., Globe Life, Inc. and Gulf Canada Resources, among others, and is also on the Advisory Board of the University of Texas Medical Branch. He has a life-long passion for history – especially of Texas and the Old West – and historic preservation. He earned his BA degree from the University of Texas at Austin, his LLB degree from the University of Texas Law School and a BFT degree from the American Institute of Foreign Trade (Thunderbird) in Phoenix, Arizona.
Theresa W. Fossum
Theresa W. Fossum, Director. Dr. Fossum is a world-renowned board-certified veterinary surgeon, author, and entrepreneur. Her background includes over 30 years of academic veterinary medicine. Dr. Fossum grew up on a ranch in northern Idaho, where she developed her love of animals. She has won numerous awards for her teaching and research. Dr. Fossum has served as the principal investigator for millions of dollars in research funding from industry and the federal government. She has served as a Special Assistant to the Secretary of Energy and is the founder and former Director and Executive Director of the Texas A&M Institute for Preclinical Studies (TIPS), a 60-million-dollar venture at Texas A&M University which promotes public-private partnerships to speed the development of medical devices and drugs. She has over 100 publications, 5 books, and numerous book chapters to her credit and has been invited to lecture at over 1000 international veterinary meetings. Dr. Fossum will be spearheading our efforts in veterinary research and product development.
Shawn J. Green, Ph.D
Director, Shawn brings 20+ years of operational experiences in the development of biologics, small molecules, medical devices, and life science informatics. His professional career began as a Medical Service Corp Officer at Walter Reed Army Institute of Research to develop new strategies to safeguard our soldiers against emerging infectious disease where he was awarded the U.S. Military’s Meritorious Service Medal. After completing his duties at Walter Reed, he served as SVP of Drug Discovery at EntreMed, a biotechnology company focused on developing anti-cancer drugs. As director of the thalidomide program, his work led to the development of Bristol Myers Squibb’s current drugs to treat multiple myeloma. Dr. Green served on various boards including the Virginia Biotechnology Industrial Organization, DOD Panel for immunomodulation strategies to treat infectious diseases, associate editor for ASM’s Infection Immunity. He was an associate at the Johns Hopkins and served as a dissertation advisor at Catholic and Howard University. Currently, he is an associate at the Lundquist Institute, UCLA Medical Center. Shawn received his PhD from the School of Medicine & Dentistry and MBA in finance and strategy, from the Business School at Georgetown University
Robert A. Newman, Ph.D.
Chief Science Officer, Chairman of the Scientific Advisory Board, and Director. Dr. Newman obtained his M.S. and Ph.D. degrees in Pharmacology and Toxicology from the University of Connecticut and then served in postdoctoral positions at the Medical School of the University of Georgia as well as the Department of Biochemistry at the University of Vermont. He served as a faculty member at the University of Vermont Medical School for seven years and then spent a sabbatical year at Stanford University performing research on immune targeted therapy. He spent 24 years at the University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, Texas where he held the D. B. Lane Distinguished Professorship Chair. At MDACC he served as the founder and Co-Director of the Pharmaceutical Development Center and the institution’s Analytical Center. He has published over 320 articles dealing with the preclinical and clinical pharmacology, toxicology and development of therapies for the prevention and treatment of malignant diseases.
Rick Matos, Ph.D
Phoenix Biotechnology’s Director. Dr. Matos has 32 years of experience as a pharmaceutical researcher, patent practitioner and consultant. He is an author of scientific articles and an inventor of pharmaceutical and chemical process technologies. He has integrated IP, business, R&D, regulatory, and commercialization strategies and built and managing robust large patent portfolios. Dr. Matos earned his doctorate in Bioorganic Chemistry from Texas A&M University after having completed his studies on the chemical and enzymatic synthesis of penicillin, amino acids and other natural products. He worked for The DuPont Merck Pharmaceutical Company as a Senior Research Scientist primarily on biotech large-scale process development and drug discovery in many therapeutic areas while advancing to Project Team Leader within the R&D department. After helping establish the pharmaceutical IP practice in the Dallas office of a major firm, Dr. Matos founded Innovar, L.L.C. in March of 2000.
Andrew J. Butler
Director, Mr. Butler is Vice Chairman of Cottingham & Butler, Inc. and President of SISCO and HealthCorp. Prior, he was Chief Executive Officer and President of both Butler Insurance Service, Inc. and Butler Benefit Service, Inc. He is currently a Trustee of Junior Achievement of the Heartland and on the board of the Dubuque Museum of Art. He has served as the President of the Board of Trustee’s for the Figge Art Museum, was a Director for the Third Party Administrators of America Association (TPAAA), and has service in an advisory capacity to several public and privately held organizations for both product development and managerial development matters. He earned his MBA from The College of Insurance in New York City, his BS in Finance from Babson College and holds several industry designations, Including CPCU, CEBS, CSFS, and ARM.
Macdonald T. Haskell
Director, Mr. Haskell is President of MTH Ventures, Inc., an Atlantic Beach, FL based company primarily involved in private investments. He is also Co-Founder and CEO of Murray Bros. Caddyshack® Restaurants and Licensing, Partner in the William Murray Golf apparel company, Co-Founder and CEO of 75th Street Holdings LLC and Director of Relevnt® Inc. a technology company based in Ponte Vedra Beach, FL. Mac began his career in New York at Merrill Lynch and Co. and earned his B.A. in Economics from Hobart College in 1980.
Lou Kost, Jr
Co-Founder, and Director. Mr. Kost attended the University of Texas at Austin, and St. Mary’s University in San Antonio, Texas, where he studied marketing and financial management. Mr. Kost has been at various times a venture capitalist and management consultant. Mr. Kost is a former Texas state representative who served on the Banking Committee.
Co-Founder, and Director Emeritus. Mr. Addington is a cum laude graduate from Southwestern University, Georgetown, Texas, majoring in economics and accounting. Mr. Addington received post-graduate education in various sciences at Trinity University, San Antonio, Texas. Mr. Addington has, over the course of 40 years, founded and/or operated successful enterprises ranging from chemical manufacturing to oil and gas exploration, development, and production.